T Therapeutics Closes Series B for TCR Bispecific Programs
T-Therapeutics announced a $133 million Series B on November 5 to take TCR-CD3 bispecific programs in oncology and autoimmune disease toward clinical proof of concept. The round finances development; neither program has disclosed human…
